PMN
ProMIS Neurosciences Inc.
Key Financials
Net Income
$-39719147
↓ 1529.3%
Operating Income
$-40167308
↓ 138.7%
Total Liabilities
$10.4M
↑ 330.9%
Total Assets
$9.2M
↓ 51.4%
EPS (Diluted)
$-22.61
↓ 20654.5%
Shareholders' Equity
$-1258592.00
↓ 107.6%
Cash & Equivalents
$6.1M
↓ 54.0%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/7/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| ARS | 4/9/2026 | View on SEC |
| DEFA14A | 4/9/2026 | View on SEC |
| DEF 14A | 4/9/2026 | View on SEC |
| SCHEDULE 13G | 4/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PMN |
| Company Name | ProMIS Neurosciences Inc. |
| CIK | 1374339 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | Z4 |
| Phone | 416-847-6898 |